Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
June 15, 2021 08:00 ET
|
Scipher Medicine Corporation
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...